Novavax COVID-19 vaccine (Nuvaxovid) has been provisionally approved by the Australian Therapeutic Goods Agency (TGA) for use in adolescents aged 12 to 17 years. The
On 25 March 2022, ATAGI recommended an additional winter booster dose (4th dose for most people) for the highest risk groups: the elderly, residents of
ATAGI says booster shots could soon be rolled out for children aged 12-15 years as Australia ramps up its winter prep in the face of
From today, eligible Australians aged 16 and 17 years old will be able to receive a COVID-19 booster vaccine, following recommendations from the Australian Technical
Vaccinating 5 to 11-year-old children in Australia against COVID-19 is a significant step closer, with the Therapeutic Goods Administration (TGA) provisionally approving the Comirnaty (Pfizer)